Featured News

New Phase 2 Clinical Trial: TEV-CeD2 Study

A new international study published in the journal Gastroenterology sheds light on the extensive economic burden of celiac disease. In addition to the cost of gluten-free  foods, the authors address…

On May 20 the Disease Foundation hosted its third annual award reception at Digestive Disease Week in Washington, D.C. From prestigious global research prizes to inaugural student and policy leadership awards, the event spotlighted the extraordinary contributions of individuals dedicated to improving the lives of those affected by celiac disease.

The Celiac Disease Foundation is proud to share that for the second year in a row, access to funding for celiac disease research is being made available through the U.S. DOD Congressionally Directed Medical Research Programs (DOD-CDMRP)Peer Review Medical Research Program.

The SynCeD Study is looking for adult volunteers with celiac disease to join a phase 2a clinical trial. Your participation could make a difference. 

The Cribsiders Podcast on pediatric medicine recently released an episode with a special guest, Dr. Dale Lee from Seattle Children's Hospital, about the diagnosis and management of celiac disease.

Research is pivotal to the mission of the Celiac Disease Foundation, and so I’m excited to provide you with an update on the groundbreaking findings of a recent study conducted for the European Union’s Joint Research Centre (JRC).

New research indicates that a specific set of natural memory T cells, when triggered by gluten, rapidly become destructive and cause intestinal damage in celiac disease patients.

As we look toward the summer months, the team here at the Celiac Disease Foundation is actively working on a number of new projects that are vital to elevating our mission to promote diagnosis, treatments, and a cure for celiac disease.

Congratulations to Celiac Disease Foundation research partner Takeda Pharmaceuticals and its Medical Director Dan Leffler on recent media attention for three potential celiac disease therapies.